










RES-154

Antiviral Effects of Lactococcus Lactic Strain Plasma (LC-Plasma) Against Upper Respiratory Tract Infectious Viruses.

ZhaoXuan Low 1, Owen Woo 1, Osamu Kanauchi 1,2, Pouya Hassandarvish 1,*, Vunjia Tiong 1,3,* and Sazaly AbuBakar 1,*

- ¹ Tropical Infectious Disease Research and Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia,
- ³ Department of Biomedical Science, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia,
- Institute of Health Sciences, Kirin Holdings Co., Ltd., 2-26-1, Muraoka-Higashi, Fujisawa 251-8555, Kanagawa, Japan

General understanding of immune system



Study summary (Aim & Endpoint)


To evaluate the immunostimulatory effect of LC-plasma on PBMC isolated from young, healthy Malaysian volunteers

To evaluate the antiviral effects of LC-plasma against influenza virus, and SARS-CoV-2 by ex. vivo.

To evaluate the mechanism of LC-plasma in inhibiting viral infections.


To evaluate the interferon stimulative gene (ISG) expression in cells upon LC-plasma supernatant treatment via qRT-PCR

Study design



Abstract


Viruses, like influenza and SARS-CoV-2, remain major causes of upper respiratory tract infections worldwide, with symptoms ranging from asymptomatic to lethal outcomes While antivirals and vaccines have helped ameliorate disease morbidity and mortality, these infections still pose significant challenges. Probiotics, including Lactococcus lactis strain Plasma (LC-Plasma), have recently shown antiviral effects by activating plasmacy-toid dendritic cells (pDCs), though their detailed mechanism remains unclear. In this study, we stimulated peripheral blood mononuclear cells (PBMCs) collected from healthy participants with LC-Plasma and conducted immunological analyses to investigate the immunomodulatory mechanisms of LC-Plasma. The supernatant derived from LC-Plasma-stimulated PBMCs (LCP-Sup) exhibited dose-dependent inhibition of H1N1 and SARS-CoV-2 replication. LCP-Sup significantly reduced SARS-CoV-2 viral load in Huh-7 cells. However, in the H1N1 antiviral assay using A549 cells, LCP-Sup was re-quired at a higher concentration against H1N1 in A549 cells compared to SARS-CoV-2 in Huh-7 cells. Treatment with LCP-Sup significantly upregulated interferonstimulated genes (ISGs) expression, particularly MxA, in A549 cells. While MxA showed the most notable increase, other ISGs also exhibited elevated expression levels compared to nega-tive control. Other cytokines, chemokines, and growth factors were also induced by LC-Plasma and CpG-DNA stimulation, and the effects of LC-Plasma were much higher than those of CpG-DNA. These results provide in vitro evidence of the antiviral mecha-nisms of LC-Plasma via upregulation of IFN- α and related ISGs for host defense against respiratory viruses.




th recombinant IFN-α (100 Units), CpG Sup 1:10, and

ISGs	Fold-increase in ISGs in A549			
	IFN-α (100 U)	CpG 1:10	LCP 1:10	Neg 1:10
IFITM-1	7.06 ± 1.91	5.30 ± 2.64	1.75 ± 0.88	0.67 ± 0.53
ISG15	94.50 ± 78.80	57.67 ± 85.45	7.14 ± 17.26	1.16 ± 0.74
ISG20	3.55 ± 1.92	3.35 ± 2.11	2.00 ± 2.20	1.19 ± 1.28
Mx-A	2442.00 ± 1243.00	1441.00 ± 1253.00	96.04 ± 70.30*	1.12 ± 0.77
OAS-1	6.57 ± 31.02	8.42 ± 28.68	4.82 ± 13.35	1.15 ± 1.08
RSAD2	239.60 ± 136.90	89.41 ± 122.10	12.52 ± 15.44	0.96 ± 1.77
RYDEN	5.09 ± 2.60	8.89 ± 6.85	2.37 ± 3.50	2.00 ± 5.37

Results





Conclusion

The finding suggest that enhanced IFN- α production, including other humoral factors stimulation leading to upregulation of ISGs (MxA) expression, is a possible mechanism contributing to LC-Plasma's antiviral activity against H1N1 and SARS-CoV-2.